Treatment-Resistant Hypertension Management Market Snapshot (2023 to 2033)
The global Treatment-Resistant Hypertension Management Market is expected to garner a market value of US$ 43 Million in 2023 and is expected to accumulate a market value of US$ 159.41 Million by registering a CAGR of 14% in the forecast period 2023 to 2033. The market for Treatment-Resistant Hypertension Management registered a CAGR of 11% in the historical period 2018 to 2022.
The market for Treatment-Resistant Hypertension management is driven by the increasing prevalence of hypertension globally and the growing number of patients with Treatment-Resistant Hypertension. According to the World Health Organization, hypertension is the leading cause of cardiovascular diseases and mortality worldwide, affecting over 1 billion people globally. The prevalence of Treatment-Resistant Hypertension is estimated to be around 10% to 30% of all patients with hypertension.
The management of Treatment-Resistant Hypertension typically involves the use of multiple classes of antihypertensive medications, such as diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). However, many patients with Treatment-Resistant Hypertension do not respond adequately to these medications and may require more aggressive treatment strategies.
Report Attribute
Details
Expected Market Value (2023)
US$ 43 Million
Anticipated Forecast Value (2033)
US$ 159.41 Million
Projected Growth Rate (2023 to 2033)
14% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Treatment-Resistant Hypertension Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Treatment-Resistant Hypertension Management reflected a value of 11% during the historical period, 2018 to 2022. The Treatment-Resistant Hypertension Management market has been growing rapidly in recent years due to the increasing prevalence and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.
Newer therapies for Treatment-Resistant Hypertension management are emerging, including the use of novel antihypertensive agents, such as mineralocorticoid receptor antagonists, direct renin inhibitors, and renal denervation. These therapies are expected to drive the growth of the Treatment-Resistant Hypertension management market in the coming years.
The Treatment-Resistant Hypertension management market is also expected to benefit from the increasing adoption of digital health technologies, such as telemedicine and remote patient monitoring, which enable healthcare providers to monitor patients with Treatment-Resistant Hypertension more closely and adjust their treatment plans as needed.
Moreover, the adoption of digital health technologies, such as telemedicine and remote patient monitoring, is expected to drive the growth of the Treatment-Resistant Hypertension management market. These technologies enable healthcare providers to monitor patients with Treatment-Resistant Hypertension more closely and adjust their treatment plans as needed, which can improve patient outcomes and reduce healthcare costs.
Overall, the market for Treatment-Resistant Hypertension Management is expected to register a CAGR of 14% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Treatment-Resistant Hypertension Management Market?
Increasing Prevalence of Hypertension to push market growth
The increasing prevalence of hypertension is one of the major factors driving the growth of the treatment-resistant hypertension management market. Hypertension, also known as high blood pressure, is a chronic medical condition in which the blood pressure in the arteries is persistently elevated. Hypertension is a leading risk factor for cardiovascular diseases, such as heart disease and stroke, which are major causes of morbidity and mortality worldwide.
The prevalence of hypertension is increasing globally, primarily due to lifestyle factors such as unhealthy diets, lack of physical activity, and stress. The World Health Organization (WHO) estimates that hypertension affects around 1.13 billion people worldwide, and this number is expected to increase to 1.56 billion by 2025. Hypertension is a major public health challenge, and its increasing prevalence is driving the demand for effective Treatment-Resistant Hypertension management strategies.
Patients with Treatment-Resistant Hypertension, who do not respond adequately to conventional antihypertensive therapies, represent a significant proportion of the overall hypertension patient population. According to estimates, the prevalence of Treatment-Resistant Hypertension is around 10% to 30% of all patients with hypertension. The increasing prevalence of hypertension is expected to drive the demand for Treatment-Resistant Hypertension management, leading to the growth of the Treatment-Resistant Hypertension management market.
The Treatment-Resistant Hypertension management market is expected to witness significant growth due to the increasing adoption of newer treatment options, including mineralocorticoid receptor antagonists, direct renin inhibitors, and renal denervation. These therapies have shown promising results in clinical trials and are expected to become more widely adopted as their efficacy and safety are established.
In summary, the increasing prevalence of hypertension is a major factor driving the growth of the Treatment-Resistant Hypertension management market. As the global burden of hypertension continues to rise, the demand for effective Treatment-Resistant Hypertension management strategies is likely to increase, leading to the growth of the Treatment-Resistant Hypertension management market.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Treatment-Resistant Hypertension Management Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of Treatment-Resistant Hypertension management can be high, particularly when multiple medications and interventions are required. This can be a significant barrier to access for patients, particularly in low- and middle-income countries.
Additionally, Patients with Treatment-Resistant Hypertension may struggle with adherence to complex treatment regimens, which can limit the effectiveness of treatment. There is a need for interventions that can improve patient adherence and engagement in their care. In summary, the Treatment-Resistant Hypertension management market faces several challenges, including the lack of effective treatment options, high cost of treatment, limited awareness and screening, adherence to treatment, and resistance to novel therapies. Addressing these challenges will be critical to improving the outcomes for patients with Treatment-Resistant Hypertension and driving the growth of the Treatment-Resistant Hypertension management market.
Region-Wise Insights
How is the Treatment-Resistant Hypertension Management Market Turning Out in the South & East Asia Region?
Increasing awareness and diagnosis of the condition Shaping Landscape for Treatment-Resistant Hypertension Management in South & East Asia
The South and East Asia region has a high burden of hypertension, and treatment-resistant hypertension is becoming increasingly prevalent in the region. The market for Treatment-Resistant Hypertension management in South and East Asia is expected to grow significantly due to the increasing prevalence of hypertension and the need for more effective Treatment-Resistant Hypertension management strategies.
One of the main drivers of the Treatment-Resistant Hypertension management market in the region is the aging population, which is at an increased risk of developing hypertension and Treatment-Resistant Hypertension. In addition, lifestyle factors, such as unhealthy diets, lack of physical activity, and stress, are contributing to the rising prevalence of hypertension in the region.
Several countries in the region, including China, India, and Indonesia, have large populations and high rates of hypertension, providing a significant market opportunity for Treatment-Resistant Hypertension management. The increasing availability of healthcare services and the adoption of newer treatment options, such as renal denervation and baroreceptor activation therapy, are also driving the growth of the Treatment-Resistant Hypertension management market in the region.
Overall, the Treatment-Resistant Hypertension management market in South and East Asia is expected to grow, driven by the increasing prevalence of hypertension and the need for more effective management strategies. However, addressing the challenges faced by the market will be critical to ensuring that patients receive the best possible care and that the market can continue to grow and innovate.
What are the Factors Boosting the Market for Treatment-Resistant Hypertension Management in North America?
Increasing Focus on Technological advancements Shaping Landscape for Treatment-Resistant Hypertension Management in North America
Hypertension is highly prevalent in North America, and the aging population is at an increased risk of developing Treatment-Resistant Hypertension. This provides a significant market opportunity for Treatment-Resistant Hypertension management. North America has a well-established healthcare system, which provides access to a wide range of treatment options for patients with Treatment-Resistant Hypertension. This includes access to specialty care and advanced therapies, such as renal denervation and baroreceptor activation therapy.
There is a strong research and development infrastructure in North America, which supports the development of new therapies for Treatment-Resistant Hypertension management. This includes collaboration between academia, industry, and government, which can accelerate the development and adoption of new treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Treatment, Which Segment is Likely to Account for a Significant Share?
Combinationtherapy segment to hold a significant share and push market growth
The combination therapy segment is likely to account for a significant share of the treatment-resistant hypertension management market. Combination therapy refers to the use of two or more medications with different mechanisms of action to achieve adequate blood pressure control in patients with Treatment-Resistant Hypertension.
Combination therapy is often necessary in patients with Treatment-Resistant Hypertension who do not respond to monotherapy or have significant comorbidities. Commonly used combinations include diuretics with ACE inhibitors or ARBs, beta-blockers with CCBs, and MRAs with ACE inhibitors or ARBs.
The combination therapy segment is likely to account for a significant share of the Treatment-Resistant Hypertension management market due to several factors. First, combination therapy is often more effective at lowering blood pressure than monotherapy, particularly in patients with Treatment-Resistant Hypertension. Second, the availability of multiple medications with different mechanisms of action allows physicians to tailor treatment to individual patients, which can improve treatment outcomes. Finally, the development of fixed-dose combination medications, which combine two or more medications in a single pill, is driving innovation in the market and providing new treatment options for patients with Treatment-Resistant Hypertension.
By Distribution Channel, Which Segment is Likely to Account for a Significant Share?
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies play a critical role in the management of Treatment-Resistant Hypertension, as they are often the first point of contact for patients with severe hypertension and Treatment-Resistant Hypertension. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of Treatment-Resistant Hypertension.
In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with Treatment-Resistant Hypertension. This team-based approach is critical for the management of Treatment-Resistant Hypertension, as it allows for individualized treatment plans that address the unique needs of each patient
Market Competition
Key players in the market include companies such as Competition Deep Dive, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, Abbott, Kona Medical, Inc., Medtronic along with healthcare providers and technology companies among other global players.
The findings of a phase II trial, conducted by a researcher from Queen Mary University of London in collaboration with colleagues at CinCor Pharma, USA, indicate that a novel drug named Baxdrostat can effectively decrease high blood pressure (hypertension) in patients who may not respond to existing treatments for the condition. Baxdrostat functions by hindering the body's production of aldosterone, a hormone that governs the salt levels in the body. The drug successfully reduced the levels of aldosterone in the blood and urine. The study demonstrated that Baxdrostat resulted in a considerable decrease in blood pressure among patients who exhibit resistance to standard medications for hypertension, which is attributed, in part, to excessive production of the aldosterone hormone.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 43 Million
Market Value in 2033
US$ 159.41 Million
Growth Rate
CAGR of 14% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Distribution Channel
Treatment
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Rest of Latin America
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Malaysia
Singapore
China
India
Thailand
Rest of South Asia
Gulf Cooperation Council
Japan
South Korea
Australia
New Zealand
GCC countries
South Africa
Israel
Rest of MEA
Key Companies Profiled
Competition Deep Dive, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, Abbott, Kona Medical, Inc., Medtronic
Customization
Available Upon Request
Key Segments Profiled in the Treatment-Resistant Hypertension Management Industry Survey
Treatment:
Diuretic therapy
Combination therapy
Mineralocorticoid receptor antagonists
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the Current Estimated Valuation of the Treatment-Resistant Hypertension Management Market?
The treatment-resistant hypertension management market is set to reach US$ 43 million in 2023.
What are the Projected Dimensions of the Treatment-Resistant Hypertension Management Market by 2033?
The treatment-resistant hypertension management market is likely to surge at an extraordinary 14% CAGR, reaching US$ 159.41 million by 2033.
What are the Prominent Factors Fueling the Adoption of Treatment-Resistant Hypertension Management?
The adoption of treatment-resistant hypertension management is driven by the rising prevalence of the condition and increased focus on comorbidities.
What are the Key Challenges faced by Treatment-Resistant Hypertension Management Market Players?
Challenges in treatment-resistant hypertension management include patient non-adherence, complex regimens, and adapting to diverse populations.
Which Country Exhibits Significant Profitability Potential for Treatment-Resistant Hypertension Management?
The United States offers lucrative potential for treatment-resistant hypertension management with its advanced healthcare and high prevalence.
Table of Content
1. Executive Summary | Treatment-Resistant Hypertension Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Diuretic therapy
5.3.2. Combination therapy
5.3.3. Mineralocorticoid receptor antagonists
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By Distribution Channel
15.6. United kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By Distribution Channel
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By Distribution Channel
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By Distribution Channel
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Idorsia Ltd
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Janssen Biotech
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Quantum Genomics SA
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. CinCor Pharma
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Ionis Pharmaceuticals
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Vifor Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. KBP Biosciences
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Abbott
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Kona Medical, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Medtronic
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033
Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 107: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 115: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
